At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Study for Patients with Completely Resected Stage IB to Stage IIIA Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
This randomized, active-controlled, multi-center, open-label, phase III study is designed to compare the effects, good or bad, of alectinib versus platinum-based chemotherapy for patients with a specific type of lung cancer. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily for 24 months. Participants in the control arm will receive a platinum based chemotherapy regimen for 4 cycles. Following treatment completion, participants will be followed until disease recurrence.
In order to participate you must meet the following criteria:
- Are at least 18 yearsof age.
- Have complete resection of histologically confirmed stage IB (tumor ≥ 4 cm) to stage IIIA (T2-3 N0, T1-3 N1, T1-3 N2, T4 N0-1) non-small cell lung cancer.
- Have documented ALK-positive disease.
You will be excluded from the study if any of the following criteria apply to you:
- Have had prior adjuvant radiotherapy or exposure to systemic chemotherapy and ALK inhibitors.
- Are a stage IIIA N2 patient that, in the investigator's opinion, should receive post-operative radiotherapy treatment.
This is a partial list of inclusion and exclusion criteria.